Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Superluminal Medicines Inc.

start up
United States - Boston, MA
  • 04/09/2023
  • Seed
  • $33,000,000

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.

Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.

The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.

With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.


Related People

Ajay YekkiralaCo Founder

Ajay Yekkirala United States - Suffolk County, Massachusetts

- Dynamic thought leader and serial inventor with over 17 years of industry and academic experience in life science drug discovery and development.
- Biotech entrepreneur with successful track record in raising capital and capacity to disrupt the CNS disease space.
- Solid team leadership and collaboration skills to build BD and scientific strategy by bringing together network of KOLs, SMEs and investors.